tm logo

Monitor this mark

View On USPTO

LUMZURALI
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 14 Aug 2024

Last Applicant/ Owned by

Sage Therapeutics, Inc.

215 First Street

Cambridge

MA

02142

Serial Number

97828313 filed on 08th Mar 2023

Registration Number

N/A

Correspondent Address

Steven A. Abreu

Steven A. Abreu SUNSTEIN LLP

BOSTON, MA 02110

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

LUMZURALI

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, depression, anxiety disorder, and bipolar depression

Classification Information

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, depression, anxiety disorder, and bipolar depression

First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details

Serial Number

No 97828313

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 4362/2044

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History

Show more

Status DateAction Taken
14th Aug 2024SOU EXTENSION 1 GRANTED
14th Aug 2024SOU EXTENSION 1 FILED
14th Aug 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14th Aug 2024SOU TEAS EXTENSION RECEIVED
05th Mar 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09th Jan 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09th Jan 2024PUBLISHED FOR OPPOSITION
20th Dec 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06th Dec 2023ASSIGNED TO EXAMINER
06th Dec 2023APPROVED FOR PUB - PRINCIPAL REGISTER